A systematic review of as needed versus treat and extend ranibizumab or bevacizumab treatment regimens for neovascular age-related macular degeneration
Conclusions
Though our study suggests superiority of the treat and extend regimen to PRN treatment in a 12-month period, this review demonstrates the need for randomised clinical trials to confirm our findings and to evaluate long-term efficacy outcomes with these regimens compared with monthly therapy.
Source: British Journal of Ophthalmology - Category: Opthalmology Authors: Chin-Yee, D., Eck, T., Fowler, S., Hardi, A., Apte, R. S. Tags: Retina Original articles - Clinical science Source Type: research
More News: Age-Related Macular Degeneration (AMD) | Avastin | Clinical Trials | Databases & Libraries | Lucentis | Opthalmology | Ranibizumab Injection | Science | Study